NetworkNewsBreaks – IGC Pharma Inc. (NYSE Americ
Post# of 430
(Total Views: 122)
Posted On: 06/06/2023 4:10:39 PM
NetworkNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501
IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada and certain European countries. IGC provided animal data (dogs) on the reduction in the number of seizures by using a combination of cannabidiol (“CBD”) and phenobarbital versus either alone. The company intends to pursue the combination in further trials with a goal to monetize the formulation as soon as practical. One potential market is dogs in America, which represents approximately 63.4 million dogs with about 1 in 20 with the potential to experience a seizure in their lifetime. IGC’s intellectual property includes over 40 filed patent applications in various countries, including the United States.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada and certain European countries. IGC provided animal data (dogs) on the reduction in the number of seizures by using a combination of cannabidiol (“CBD”) and phenobarbital versus either alone. The company intends to pursue the combination in further trials with a goal to monetize the formulation as soon as practical. One potential market is dogs in America, which represents approximately 63.4 million dogs with about 1 in 20 with the potential to experience a seizure in their lifetime. IGC’s intellectual property includes over 40 filed patent applications in various countries, including the United States.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)IGC Pharma Inc. (IGC) Stock Research Links
Scroll down for more posts ▼